The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

Background For postmenopausal women with hormone-receptor–positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Background Extending the duration of adjuvant endocrine therapy reduces the risk of
recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast …

Purpose: Individualized selection of patients with early-stage hormone receptor–positive
(HR+) breast cancer for extended endocrine therapy (EET) is required to balance modest …

Background: Endocrine therapy with a standard duration of 5 years is well known as an
effective treatment for endocrine-sensitive breast cancer. Summary: In the adjuvant setting …

Polycystic ovarian syndrome (PCOS) is the primary cause of female infertility affecting
several women worldwide. Changes in hormonal functions such as hyperandrogenism are …